Adicet Bio (ACET)
(Delayed Data from NSDQ)
$0.91 USD
-0.01 (-1.12%)
Updated Oct 22, 2025 04:00 PM ET
After-Market: $0.91 0.00 (-0.18%) 7:48 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACET 0.91 -0.01(-1.12%)
Will ACET be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ACET based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACET
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
ACET: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Other News for ACET
ACET forms 20 Day Moving Average Support on October 21
ACET forms NR7 on October 20
ACET forms Upper Bollinger Band Walk on October 17
ACET forms Upper Bollinger Band Walk on October 16
Canaccord Genuity Remains a Buy on Adicet Bio (ACET)